Followers | 55 |
Posts | 2608 |
Boards Moderated | 0 |
Alias Born | 02/04/2014 |
Tuesday, October 27, 2015 11:11:26 AM
Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, announced the appointment of Dr. Miguel Barbosa, Ph.D. as Executive Vice President and Chief Scientific Officer.
Dr. Barbosa has joined the Company with 20 years of biopharmaceutical research discovery experience. For the past decade, he served in senior leadership roles at several Johnson & Johnson subsidiaries. Most recently, Dr. Barbosa was Executive in Residence, Therapeutic Innovation at Johnson & Johnson Innovation, where he led the identification and development of new R&D and business models. Prior to that, he was Vice President, Immunology Research & External Innovation, at Janssen Research & Development L.L.C., also a J&J company, where he led immunology discovery and translational research programs. Earlier in his career, he served as Vice President, Discovery Research, at J&J’s Centocor Research & Development, Inc.
“We are pleased to welcome Miguel to the role of Chief Scientific Officer,” said Paul Lammers, M.D., M.Sc., Mirna's President and Chief Executive Officer. “As a highly accomplished industry executive with a proven ability to lead top research and development programs, we are confident Miguel’s expertise and strategic vision, particularly in emerging areas of science, will prove critical as we advance our pipeline of microRNA-based oncology therapeutics.”
Dr. Barbosa received a B.S. in Genetics from the University of California, Davis, and a Ph.D. in Microbiology & Immunology from the University of California, Los Angeles, and completed his training at the National Cancer Institute.
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM